Almirall appoints Gianfranco Nazzi as new CEO

8 February 2021

Spanish skincare specialist Almirall (ALM: MC) has appointed Gianfranco Nazzi as chief executive and executive director of the board of directors effective May 1, 2021.

Mr Nazzi joins Almirall from Teva Pharmaceuticals Industries (NYSE: TEVA), where he has most recently been serving as executive vice president of the International Markets Region and as a member of the Teva executive committee. While at Teva over the past seven years, he has held roles of increasing responsibility and geographic scope based in Israel and the Netherlands. Prior to Teva Mr Nazzi held a variety of senior positions in Astra Zeneca (LSE: AZN), GlaxoSmithKline (LSE: GSK) and Eli Lilly (NYSE: LLY) in commercial and general management roles based in the UK, Italy, Serbia and the US.

“I´m very pleased to announce that the Board of Directors have agreed to appoint Gianfranco Nazzi. Mr Nazzi is a trusted leader in the Pharma industry and brings with him a wealth of experience in areas key to the success and growth of Almirall, in US, Europe and Emerging Markets. I am convinced he will bring what is needed to develop Almirall to the next level,” said Jorge Gallardo, chairman and president of Almirall.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK